ATE448247T1 - Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz - Google Patents
Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenzInfo
- Publication number
- ATE448247T1 ATE448247T1 AT05020718T AT05020718T ATE448247T1 AT E448247 T1 ATE448247 T1 AT E448247T1 AT 05020718 T AT05020718 T AT 05020718T AT 05020718 T AT05020718 T AT 05020718T AT E448247 T1 ATE448247 T1 AT E448247T1
- Authority
- AT
- Austria
- Prior art keywords
- glp
- peptide
- component
- sequence
- glucagon
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 title abstract 6
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 6
- 230000004927 fusion Effects 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 title 2
- 229920001184 polypeptide Polymers 0.000 title 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 abstract 1
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 abstract 1
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 abstract 1
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 208000034615 apoptosis-related disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05020718A EP1767545B1 (de) | 2005-09-22 | 2005-09-22 | Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE448247T1 true ATE448247T1 (de) | 2009-11-15 |
Family
ID=35700191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05020718T ATE448247T1 (de) | 2005-09-22 | 2005-09-22 | Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz |
Country Status (23)
Country | Link |
---|---|
US (2) | US8431533B2 (de) |
EP (5) | EP1767545B1 (de) |
JP (2) | JP5222729B2 (de) |
KR (1) | KR20080064840A (de) |
CN (1) | CN101273058A (de) |
AT (1) | ATE448247T1 (de) |
AU (1) | AU2006299134B2 (de) |
BR (1) | BRPI0616107A2 (de) |
CA (1) | CA2619053A1 (de) |
CY (1) | CY1109778T1 (de) |
DE (1) | DE602005017628D1 (de) |
DK (1) | DK1767545T3 (de) |
EA (1) | EA013796B1 (de) |
ES (3) | ES2397289T3 (de) |
HR (1) | HRP20100062T1 (de) |
IL (1) | IL188904A0 (de) |
PL (1) | PL1767545T3 (de) |
PT (1) | PT1767545E (de) |
RS (1) | RS51319B (de) |
SG (1) | SG165414A1 (de) |
SI (1) | SI1767545T1 (de) |
WO (1) | WO2007039140A1 (de) |
ZA (1) | ZA200803488B (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2397289T3 (es) | 2005-09-22 | 2013-03-06 | Biocompatibles Uk Ltd. | Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada |
WO2007049940A1 (en) * | 2005-10-27 | 2007-05-03 | Peptron Co., Ltd | Bioactive substance-blood protein conjugate and stabilization of a bioactive substance using the same |
US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
DE602006009631D1 (de) | 2006-05-10 | 2009-11-19 | Biocompatibles Uk Ltd | GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung |
EP1972349A1 (de) * | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung |
EP1975176A1 (de) * | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung |
EP3412300A1 (de) * | 2008-06-27 | 2018-12-12 | Duke University | Therapeutika mit elastinähnlichen peptiden |
EP2163243A1 (de) * | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern |
CN101993485B (zh) * | 2009-08-20 | 2013-04-17 | 重庆富进生物医药有限公司 | 促胰岛素分泌肽类似物同源二聚体及其用途 |
JP5749744B2 (ja) * | 2010-02-11 | 2015-07-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Igf−iポリ(エチレングリコール)コンジュゲート |
WO2012043397A1 (ja) * | 2010-10-01 | 2012-04-05 | 株式会社エム・エム・ティー | イミュノグロブリン結合能を有するペプチド |
CN102766204B (zh) * | 2011-05-05 | 2014-10-15 | 天津药物研究院 | 胰高血糖素样肽-1突变体多肽及其制备方法和其应用 |
CN102363633B (zh) * | 2011-11-16 | 2013-11-20 | 天津拓飞生物科技有限公司 | 胰高血糖素样肽-1突变体多肽及其制备方法、药物组合物和其应用 |
US11065304B2 (en) | 2012-11-20 | 2021-07-20 | Mederis Diabetes, Llc | Peptide pharmaceuticals for insulin resistance |
CN104371019B (zh) * | 2013-08-13 | 2019-09-10 | 鸿运华宁(杭州)生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
CN104707131A (zh) * | 2013-12-13 | 2015-06-17 | 上海建华精细生物制品有限公司 | 一种药物组合物及其制备方法和用途 |
CN113264994A (zh) | 2014-05-28 | 2021-08-17 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
DK3257524T3 (da) | 2015-02-11 | 2020-11-23 | Gmax Biopharm Llc | Stabiliseret opløsningspræparat af farmaceutisk glp-1r-antistoffusionsprotein |
US11123405B2 (en) | 2015-12-23 | 2021-09-21 | The Johns Hopkins University | Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions |
CN107818433B (zh) * | 2016-09-14 | 2022-07-05 | 菜鸟智能物流控股有限公司 | 取件方法、物流信息处理方法及装置、系统 |
WO2018104559A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Glp-1/glp-2 dual agonists |
WO2018104558A1 (en) * | 2016-12-09 | 2018-06-14 | Zealand Pharma A/S | Acylated glp-1/glp-2 dual agonists |
SG11201903938XA (en) | 2016-12-09 | 2019-05-30 | Zealand Pharma As | Acylated glp-1/glp-2 dual agonists |
CN108341880B (zh) * | 2017-01-23 | 2023-07-04 | 天津药物研究院有限公司 | 含有胰高血糖素样肽-1和胰高血糖素的片段类似物的嵌合多肽及其用途 |
KR101827245B1 (ko) * | 2017-12-26 | 2018-02-08 | (주)제이유타이드 | 알라린을 주성분으로 하는 요독증 치료제 |
CA3086918A1 (en) | 2018-01-03 | 2019-07-11 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for treatment of nash and other disorders |
KR101903564B1 (ko) * | 2018-01-31 | 2018-11-13 | 한국지질자원연구원 | 제지공정에서 발생되는 부산물의 재활용 방법 |
EP3774862B1 (de) | 2018-04-05 | 2022-06-08 | Sun Pharmaceutical Industries Limited | Neuartige glp-1-analoga |
WO2020125744A1 (zh) | 2018-12-21 | 2020-06-25 | 江苏恒瑞医药股份有限公司 | 双特异性蛋白 |
KR102349717B1 (ko) * | 2020-03-12 | 2022-01-11 | 주식회사 에스엘메타젠 | 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물 |
WO2021182928A1 (ko) * | 2020-03-12 | 2021-09-16 | 주식회사 에스엘메타젠 | 신규 이중 특이성 단백질 및 그의 용도 |
WO2022015039A1 (ko) * | 2020-07-14 | 2022-01-20 | (주)지아이이노베이션 | 글루카곤-유사 펩타이드-1 및 글루카곤-유사 펩타이드-2를 포함하는 융합 단백질 및 이의 용도 |
GB2616223A (en) * | 2020-11-27 | 2023-08-30 | D&D Pharmatech Inc | Oral formulation of biologically active material conjugate having biotin moiety, fatty acid moiety, or combination thereof coupled thereto |
EP4252780A1 (de) * | 2020-11-27 | 2023-10-04 | D&D Pharmatech Inc. | Biologisch aktives konjugat mit biotinteil, fettsäureteil oder kombination davon, die daran gekoppelt sind |
CN112661862B (zh) * | 2020-12-25 | 2023-03-31 | 深圳大学 | 一种融合蛋白及其制备方法和应用 |
CN113846124A (zh) * | 2021-09-26 | 2021-12-28 | 康霖生物科技(杭州)有限公司 | 一种用于糖代谢相关疾病基因治疗的核酸构建体 |
CN114874314B (zh) * | 2021-12-28 | 2022-11-11 | 北京惠之衡生物科技有限公司 | 一种高表达glp-1类似物的重组工程菌及其构建方法 |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US586128A (en) * | 1897-07-13 | Toilet-paper holder | ||
US4352883A (en) * | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
ATE6548T1 (de) | 1979-10-16 | 1984-03-15 | Winfried Dr. Med. Stoecker | Vorrichtung zur durchfuehrung von mikroanalysen. |
US4596792A (en) | 1981-09-04 | 1986-06-24 | The Regents Of The University Of California | Safe vaccine for hepatitis containing polymerized serum albumin |
JPS5938877A (ja) | 1982-08-30 | 1984-03-02 | Musashi Eng Kk | 紙葉判別方法 |
US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
US4588585A (en) | 1982-10-19 | 1986-05-13 | Cetus Corporation | Human recombinant cysteine depleted interferon-β muteins |
US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
DD224119A1 (de) | 1983-11-07 | 1985-06-26 | Univ Schiller Jena | Temperierbarer probentraeger |
US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4959314A (en) | 1984-11-09 | 1990-09-25 | Cetus Corporation | Cysteine-depleted muteins of biologically active proteins |
US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
US5144139A (en) | 1985-08-05 | 1992-09-01 | Biotrack, Inc. | Capillary flow device |
US4687529A (en) | 1985-08-30 | 1987-08-18 | Miles Laboratories, Inc. | Method of making a reagent test device containing hydrophobic barriers |
CA1292176C (en) | 1985-09-18 | 1991-11-19 | Joel M. Blatt | Volume metering capillary gap device for applying a liquid sample onto a reactive surface |
US5017691A (en) | 1986-07-03 | 1991-05-21 | Schering Corporation | Mammalian interleukin-4 |
US6849708B1 (en) | 1986-05-05 | 2005-02-01 | The General Hospital Corporation | Insulinotropic hormone and uses thereof |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
DE69129226T2 (de) | 1990-01-24 | 1998-07-30 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
EP0499990B1 (de) | 1991-02-19 | 1996-05-15 | Takeda Chemical Industries, Ltd. | Verfahren zur Herstellung von cysteinfreien Peptiden |
CA2062338A1 (en) | 1991-03-15 | 1992-09-16 | Zia Yassinzadeh | Electronic control cartridge and method of simulating light transmission patterns |
GB9311147D0 (en) | 1993-05-28 | 1993-07-14 | Long Ashton Research Station | Regulation of plant growth |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
BE1008987A3 (fr) | 1995-01-06 | 1996-10-01 | Robyn Pierre | Blocs refractaires a canalisations pour sols de fours verriers et installation dans les sols de circuits de refroidissement ou de chauffage, permettant d'ameliorer le controle thermique des sols et la qualite du verre. |
JP3643863B2 (ja) | 1995-08-09 | 2005-04-27 | アークレイ株式会社 | 液体保持具とその製造方法 |
EP1975177B1 (de) | 1996-03-01 | 2011-04-13 | Novo Nordisk A/S | Appetithemmendes Peptid, Zusammensetzung und Verwendung |
US6165739A (en) | 1996-03-13 | 2000-12-26 | Compucyte Corporation | Multiple simultaneous testing media |
DK0966297T4 (da) | 1996-08-08 | 2013-03-18 | Amylin Pharmaceuticals Llc | Regulering af gastrointestinal motilitet |
PT944648E (pt) * | 1996-08-30 | 2007-06-26 | Novo Nordisk As | Derivados do glp-1. |
DE69732572T2 (de) | 1996-11-12 | 2005-12-29 | Novo Nordisk A/S | Verwendung von glp-1 peptiden |
WO1999035242A1 (en) | 1998-01-12 | 1999-07-15 | Betagene, Inc. | Media for neuroendocrine cells |
WO1999044507A1 (en) | 1998-03-06 | 1999-09-10 | Spectrx, Inc. | Integrated tissue poration, fluid harvesting and analysis device, and method therefor |
IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
WO1999053064A2 (en) | 1998-04-13 | 1999-10-21 | Modex Therapeutiques, S.A. | Methods of delivering glp-1 |
US7259136B2 (en) | 1999-04-30 | 2007-08-21 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating peripheral vascular disease |
US6267954B1 (en) | 1999-11-24 | 2001-07-31 | Universite De Paris V Rene-Descartes | Intraocular transplantation of encapsulated cells |
US6706159B2 (en) | 2000-03-02 | 2004-03-16 | Diabetes Diagnostics | Combined lancet and electrochemical analyte-testing apparatus |
DE60114996T2 (de) | 2000-03-08 | 2006-08-10 | Novo Nordisk A/S | Senkung des serum cholesterols |
DE10039643A1 (de) * | 2000-08-14 | 2002-02-28 | Max Planck Gesellschaft | Funktionalisierte Perylentetracarbonsäurediimide |
SI1355942T1 (sl) | 2000-12-07 | 2009-02-28 | Lilly Co Eli | Glp-1 fuzijski proteini |
US6821485B2 (en) | 2001-02-09 | 2004-11-23 | Wisconsin Alumni Research Foundation | Method and structure for microfluidic flow guiding |
US20020183253A1 (en) | 2001-02-22 | 2002-12-05 | Brazzell Romulus Kimbro | Method of treating ocular neovascularization |
US20030034147A1 (en) | 2001-05-31 | 2003-02-20 | Houck Glenn M. | Apparatus which eliminates the need for idling by trucks |
JP5562510B2 (ja) | 2001-06-28 | 2014-07-30 | ノヴォ ノルディスク アー/エス | 修飾glp−1の安定な処方剤 |
CN1363654A (zh) * | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | 生产促胰岛素分泌肽glp-1(7-36)的基因工程菌以及生产glp-1(7-36)的方法 |
EP1430115A1 (de) | 2001-07-27 | 2004-06-23 | Arhus Amt | Immortalisierte stammzellen |
AU2002317599B2 (en) | 2001-07-31 | 2008-04-03 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | GLP-1 exendin-4 peptide analogs and uses thereof |
US20040143104A1 (en) | 2001-08-08 | 2004-07-22 | Wadsworth Samuel C. | Methods of treating diabetes and other blood sugar disorders |
JP2005508895A (ja) | 2001-08-28 | 2005-04-07 | イーライ・リリー・アンド・カンパニー | Glp−1および基礎インスリンの予備混合物 |
US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
US7166208B2 (en) | 2004-03-03 | 2007-01-23 | Stephen Eliot Zweig | Apoenzyme reactivation electrochemical detection method and assay |
ATE352312T1 (de) | 2001-12-29 | 2007-02-15 | Novo Nordisk As | Kombinierte verwendung einer glp-1-verbindung und eines aldose reduktase inhibitors |
AU2003200839B2 (en) * | 2002-01-08 | 2008-12-11 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
GB2388898B (en) | 2002-04-02 | 2005-10-05 | Inverness Medical Ltd | Integrated sample testing meter |
US20030191056A1 (en) * | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
US20030143113A2 (en) | 2002-05-09 | 2003-07-31 | Lifescan, Inc. | Physiological sample collection devices and methods of using the same |
WO2004022004A2 (en) | 2002-09-06 | 2004-03-18 | Bayer Pharmaceuticals Corporation | Modified glp-1 receptor agonists and their pharmacological methods of use |
JP4548335B2 (ja) * | 2003-03-07 | 2010-09-22 | 味の素株式会社 | 腸管細胞のインスリン産生細胞への変換誘導剤、及び糖尿病治療剤 |
US6969166B2 (en) | 2003-05-29 | 2005-11-29 | 3M Innovative Properties Company | Method for modifying the surface of a substrate |
US7057116B2 (en) | 2003-06-02 | 2006-06-06 | Intel Corporation | Selective reference plane bridge(s) on folded package |
MXPA05013565A (es) * | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion analogas al glp-1. |
EP1498143A1 (de) | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Selbstemulgierende und selbstmicroemulgierende Formulierungen zur oralen Verabreichung von Taxoiden |
WO2005014035A2 (en) | 2003-08-08 | 2005-02-17 | Novo Nordisk Health Care Ag | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
CN100580087C (zh) | 2003-10-10 | 2010-01-13 | 诺和诺德医疗保健公司 | 肽的缀合 |
CA2550050A1 (en) * | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 analogues linked to albumin-like agents |
WO2005072216A2 (en) | 2004-01-20 | 2005-08-11 | The Curators Of The University Of Missouri | Supported molecular biofluid viscosity sensors for in vitro and in vivo use |
AU2005211755B2 (en) | 2004-02-11 | 2012-03-15 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
DE602004011688D1 (de) | 2004-03-05 | 2008-03-20 | Egomedical Swiss Ag | Analyttestsystem zur bestimmung der konzentration eines analyten in einer physiologischen flüssigkeit |
KR20070004078A (ko) | 2004-03-31 | 2007-01-05 | 센토코 인코포레이티드 | 인간 glp-1 모방체, 조성물, 방법 및 용도 |
US20080300173A1 (en) * | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
PT1776464E (pt) | 2004-08-13 | 2010-01-06 | Egomedical Technologies Ag | Sistema de teste de analitos para determinar a concentração de um analito num fluido fisiológico ou aquoso |
US7442682B2 (en) | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
CA2616551A1 (en) | 2005-07-29 | 2007-02-15 | Amprotein Corporation | Chimeric therapeutic agents |
ES2397289T3 (es) | 2005-09-22 | 2013-03-06 | Biocompatibles Uk Ltd. | Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a peptidasa incrementada |
DE602006009631D1 (de) | 2006-05-10 | 2009-11-19 | Biocompatibles Uk Ltd | GLP-1 Peptide enthaltende kugelförmige Mikrokapseln, deren Produktion und deren Verwendung |
EP1972349A1 (de) | 2007-03-21 | 2008-09-24 | Biocompatibles UK Limited | Mit Polymer(en) konjugierte GLP-1-Fusionspeptide, ihre Herstellung und Verwendung |
EP1975176A1 (de) | 2007-03-27 | 2008-10-01 | Biocompatibles UK Limited | Neue GLP-1-Fusionspeptide, ihre Herstellung und Verwendung |
EP2163243A1 (de) | 2008-09-12 | 2010-03-17 | Biocompatibles UK Limited | Behandlung akuter Herzinfarkte mithilfe eingekapselter Zellen, welche GLP-1-Peptide oder deren Analoga kodieren und absondern |
-
2005
- 2005-09-22 ES ES08021837T patent/ES2397289T3/es active Active
- 2005-09-22 AT AT05020718T patent/ATE448247T1/de active
- 2005-09-22 DE DE602005017628T patent/DE602005017628D1/de active Active
- 2005-09-22 RS RSP-2010/0039A patent/RS51319B/sr unknown
- 2005-09-22 PT PT05020718T patent/PT1767545E/pt unknown
- 2005-09-22 PL PL05020718T patent/PL1767545T3/pl unknown
- 2005-09-22 SI SI200530887T patent/SI1767545T1/sl unknown
- 2005-09-22 DK DK05020718.2T patent/DK1767545T3/da active
- 2005-09-22 EP EP05020718A patent/EP1767545B1/de active Active
- 2005-09-22 EP EP08021837A patent/EP2045265B1/de active Active
- 2005-09-22 ES ES05020718T patent/ES2336575T3/es active Active
-
2006
- 2006-09-22 AU AU2006299134A patent/AU2006299134B2/en not_active Ceased
- 2006-09-22 ZA ZA200803488A patent/ZA200803488B/xx unknown
- 2006-09-22 CA CA002619053A patent/CA2619053A1/en not_active Abandoned
- 2006-09-22 KR KR1020087009543A patent/KR20080064840A/ko not_active Application Discontinuation
- 2006-09-22 EP EP09014513A patent/EP2174952A3/de not_active Withdrawn
- 2006-09-22 EP EP10009718A patent/EP2261245A1/de not_active Withdrawn
- 2006-09-22 SG SG201006921-9A patent/SG165414A1/en unknown
- 2006-09-22 WO PCT/EP2006/009226 patent/WO2007039140A1/en active Application Filing
- 2006-09-22 US US11/991,562 patent/US8431533B2/en not_active Expired - Fee Related
- 2006-09-22 EP EP06792228A patent/EP1926748B1/de not_active Not-in-force
- 2006-09-22 BR BRPI0616107-3A patent/BRPI0616107A2/pt not_active IP Right Cessation
- 2006-09-22 JP JP2008531616A patent/JP5222729B2/ja not_active Expired - Fee Related
- 2006-09-22 ES ES06792228T patent/ES2394218T3/es active Active
- 2006-09-22 CN CNA2006800350367A patent/CN101273058A/zh active Pending
- 2006-09-22 EA EA200800699A patent/EA013796B1/ru not_active IP Right Cessation
-
2008
- 2008-01-21 IL IL188904A patent/IL188904A0/en unknown
-
2010
- 2010-02-02 HR HR20100062T patent/HRP20100062T1/hr unknown
- 2010-02-11 CY CY20101100139T patent/CY1109778T1/el unknown
-
2012
- 2012-05-29 US US13/482,354 patent/US8853159B2/en not_active Expired - Fee Related
-
2013
- 2013-01-25 JP JP2013012558A patent/JP2013099352A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE448247T1 (de) | Fusionspolypeptide vom glp-1 (glucagon-like peptide-1) mit erhöhten peptidaseresistenz | |
WO2008116648A3 (en) | Novel glp-1 fusion peptides, their production and use | |
Candeias et al. | Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide | |
US20190085043A1 (en) | Fusion proteins for treating a metabolic syndrome | |
JP5580784B2 (ja) | 選択可能な特性を有するハイブリッドポリペプチド | |
JP6121330B2 (ja) | 作用持続時間が増した改変ポリペプチド | |
JP2017088627A (ja) | エラスチン様ペプチドを含む治療剤 | |
PL2301962T3 (pl) | Wynalazek dotyczący glp-1 i eksendyny | |
WO2003033671A3 (en) | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions | |
EP2390264A1 (de) | GIP-Analog und Hybridpolypeptide mit auswählbaren Eigenschaften | |
WO2006127948A3 (en) | N-terminally modified glp-1 receptor modulators | |
WO2006014287A8 (en) | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions | |
US20050137135A1 (en) | Novel analogues of glucose-dependent insulinotropic polypeptide | |
JP2016188225A (ja) | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド | |
WO2006017688A3 (en) | Combination therapy using transferrin fusion proteins comprising glp-1 | |
PE20080733A1 (es) | Proteinas de fusion de exendina | |
JP2004509079A5 (de) | ||
CA2660835A1 (en) | Dpp-iv resistant gip hybrid polypeptides with selectable propperties | |
JP6811190B2 (ja) | プロテアーゼ耐性脂質付加glp−1類似体 | |
Linderoth et al. | GLP‐1 Receptor Agonists for the Treatment of Type 2 Diabetes and Obesity | |
Oskola et al. | Angioprotektivnoe properties lowering drugs from the group of inhibitors of dipeptidyl peptidase-4 | |
TH87281A (th) | N-เทอร์มินัลลี มอดิไฟด์ glp-1 รีเซปเตอร์ มอดูเลเตอร์ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1767545 Country of ref document: EP |